Integrated models of care for people who inject drugs and live with hepatitis C virus: A systematic review

被引:51
|
作者
Socias, M. Eugenia [1 ,2 ]
Karamouzian, Mohammad [1 ,3 ]
Parent, Stephanie [4 ]
Barletta, Jose [5 ]
Bird, Kathleen [1 ]
Ti, Lianping [1 ,2 ]
机构
[1] British Columbia Ctr Subst Use, 400-1045 Howe St, Vancouver, BC V6Z 2A9, Canada
[2] Univ British Columbia, Dept Med, St Pauls Hosp, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada
[3] Kerman Univ Med Sci, Inst Futures Studies Hlth, WHO Collaborating Ctr HIV Surveillance, HIV STI Surveillance Res Ctr, Kerman 7616911320, Iran
[4] St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada
[5] Hosp Juan A Fernandez, Div Infect Dis, Cervino 3356,C1425AGP, Buenos Aires, DF, Argentina
基金
加拿大健康研究院;
关键词
Hepatitis C; People who inject drugs; People who use drugs; Substance use disorder; Integrated care; Systematic review; DIRECTLY OBSERVED THERAPY; ANTIVIRAL TREATMENT; TREATMENT SERVICES; USERS; INFECTION; PROGRAM; HIV; RISK; DETERMINANTS; FEASIBILITY;
D O I
10.1016/j.drugpo.2019.05.023
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Despite the key role that people who inject drugs (PWID) play in the hepatitis C virus (HCV) epidemic, HCV treatment rates among this population have been historically low. Integrated models of HCV and substance use care have the potential to overcome some barriers to access; however, the evidence base is uncertain. This systematic review assesses the impacts of integrated HCV and substance use services on engagement in HCV care among PWID. Methods: We searched five databases up to December 2018 to identify original quantitative studies evaluating the impacts of co-location of HCV and substance use services on engagement in the HCV cascade of care among adult PWID. We conducted a narrative synthesis, categorizing models based on patient entry point (a: HCV facility, b: substance use disorder (SUD) facility, and c: other facilities), and levels of integrated services offered (a: HCV/substance use testing only, b: HCV/substance use treatment, and c: testing/treatment + other services). Results: A total of 46 articles corresponding to 44 original studies were included. Almost all studies (n = 42) were conducted in high-income countries and only six studies in the Direct-Acting Antiviral (DAA) era. Twenty-six studies discussed the integration of services at SUD facilities, one at HCV facilities, and seventeen at other facilities. Analysis of included studies indicated that overall integrated care resulted in improved engagement in HCV care (e.g., testing, treatment uptake and cure). However, the quality of evidence was predominantly low to moderate. Conclusions: Available evidence suggests that integration of HCV and substance use services may improve engagement along the continuum of HCV care among PWID. Given limitations in data quality, and very few studies conducted in the DAA era and in low- and middle-income settings, further research is urgently needed to inform strategies to optimize HCV care access and outcomes among PWID globally.
引用
收藏
页码:146 / 159
页数:14
相关论文
共 50 条
  • [1] MODELS OF CARE FOR THE MANAGEMENT AND TREATMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS
    Conti, Fabio
    Borghi, Alberto
    Lanzi, Arianna
    Bevilacqua, Vittoria
    Vignoli, Teo
    Olivoni, Deanna
    Greco, Giovanni
    Sanza, Michele
    Polidori, Edoardo
    Bassi, Paolo
    Grassi, Alberto
    Ballardini, Giorgio
    Piraccini, Pierpaolo
    Sambri, Vittorio
    Foschi, Francesco Giuseppe
    [J]. HEPATOLOGY, 2019, 70 : 956A - 956A
  • [2] Models of care for the management and treatment of hepatitis C virus infection among people who inject drugs
    Conti, F.
    Borghi, A.
    Lanzi, A.
    Bevilacqua, V.
    Vignoli, T.
    Olivoni, D.
    Greco, G.
    Sanza, M.
    Polidori, E.
    Bassi, P.
    Foschi, F. G.
    [J]. DIGESTIVE AND LIVER DISEASE, 2019, 51 : E60 - E61
  • [3] A review of network simulation models of hepatitis C virus and HIV among people who inject drugs
    Bellerose, Meghan
    Zhu, Lin
    Hagan, Liesl M.
    Thompson, William W.
    Randall, Liisa M.
    Malyuta, Yelena
    Salomon, Joshua A.
    Linas, Benjamin P.
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2021, 88
  • [4] Hepatitis C cascade of care at an integrated community facility for people who inject drugs
    Morris, Leith
    Selvey, Linda
    Williams, Owain
    Gilks, Charles
    Kvassy, Amanda
    Smirnov, Andrew
    [J]. JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2020, 114
  • [5] Hepatitis C Virus Dynamic Transmission Models Among People Who Inject Drugs
    Woyesa, Shiferaw Bekele
    Amente, Kellemuwa Desalegn
    [J]. INFECTION AND DRUG RESISTANCE, 2023, 16 : 1061 - 1068
  • [6] A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region
    Jeffrey V Lazarus
    Ida Sperle
    Mojca Maticic
    Lucas Wiessing
    [J]. BMC Infectious Diseases, 14
  • [7] A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region
    Lazarus, Jeffrey V.
    Sperle, Ida
    Maticic, Mojca
    Wiessing, Lucas
    [J]. BMC INFECTIOUS DISEASES, 2014, 14
  • [8] Hepatitis C Virus Vaccines Among People Who Inject Drugs
    Cox, Andrea L.
    Thomas, David L.
    [J]. CLINICAL INFECTIOUS DISEASES, 2013, 57 : S46 - S50
  • [9] Hepatitis C virus infection in people who inject drugs in Africa
    Shah, Rajiv
    Boucheron, Pauline
    Mandaliya, Kishor
    Kattamaiyo, Alex
    Chevaliez, Stephane
    Shimakawa, Yusuke
    Songok, Elijah
    Lemoine, Maud
    [J]. LANCET INFECTIOUS DISEASES, 2020, 20 (03): : 282 - 283
  • [10] Hepatitis C virus treatment as prevention in people who inject drugs
    White, Peter J.
    Abubakar, Ibrahim
    [J]. LANCET INFECTIOUS DISEASES, 2018, 18 (04): : 379 - 379